Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 19;5(34):21610-21622.
doi: 10.1021/acsomega.0c02287. eCollection 2020 Sep 1.

Soy Protein-Based Hydrogel under Microwave-Induced Grafting of Acrylic Acid and 4-(4-Hydroxyphenyl)butanoic Acid: A Potential Vehicle for Controlled Drug Delivery in Oral Cavity Bacterial Infections

Affiliations

Soy Protein-Based Hydrogel under Microwave-Induced Grafting of Acrylic Acid and 4-(4-Hydroxyphenyl)butanoic Acid: A Potential Vehicle for Controlled Drug Delivery in Oral Cavity Bacterial Infections

Saloni Mehra et al. ACS Omega. .

Abstract

The objective of this work was to evaluate grafted soy protein isolate (SPI) for pharmaceutical applications. The present work reports the microwave-assisted preparation of soy protein isolate\grafted[acrylic acid-co-4-(4-hydroxyphenyl)butanoic acid] [SPI-g-(AA-co-HPBA)] hydrogel via graft copolymerization using N,N-methylene-bis-acrylamide and potassium persulphate as the cross-linker and initiator, respectively. The chemical and physical properties of the synthesized polymeric hydrogels were analyzed by Fourier transform infrared spectroscopy, liquid chromatography-mass spectrometry (LCMS), nuclear magnetic resonance 1H-NMR, X-ray diffraction (XRD), transmission electron microscopy (TEM), scanning electron microscopy (SEM), and thermogravimetric analysis (TGA). The SEM, TEM, and XRD analyses have confirmed the formation of hydrogel SPI-g-(AA-co-HPBA) with the network structure having a layered and crystalline surface. The SPI-g-(AA-co-HPBA) hydrogel was investigated for the sustained and controlled drug delivery system for the release of model drug ciprofloxacin at basic pH for its utilization against bacterial infection in oral cavity. The drug release profile for SPI-g-(AA-co-HPBA) hydrogels was studied using LCMS at the ppb level at pH = 7.4. The synthesized hydrogel was found to be noncytotoxic, polycrystalline in nature with a network structure having good porosity, increased thermal stability, and pH-responsive behavior. The hydrogel has potential to be used as the vehicle for controlled drug delivery in oral cavity bacterial infections.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Scheme 1
Scheme 1. Mechanism of Grafting Using Microwave Conditions
Figure 1
Figure 1
(a) Effect of heating temperature in MW on grafting, (b) effect of preheating time in MW on grafting, (c) effect of concentration of initiator on grafting, and (d) effect of monomer concentration on grafting.
Figure 2
Figure 2
Graph showing% of swelling behavior of (a) (1) SPI-g-(AA-co-HPBA), (2) neat SPI, and (3) SPI-g-AA at pH 7.4 and (b) (1) neat SPI, (2) SPI-g-AA, and (3) SPI-g-(AA-co-HPBA) at pH 1.2.
Figure 3
Figure 3
(a) Calibration curve for linearity of ciprofloxacin. (b) Absorption study of ciprofloxacin on the hydrogel by LC–MS/MS.
Figure 4
Figure 4
(a) Ciprofloxacin release study from the grafted hydrogel at pH 7.4, and (b) percentage release of ciprofloxacin from the grafted hydrogel at pH 7.4 over 14 h, using Agilent 6470 LC–MS/MS.
Figure 5
Figure 5
XRD data for neat SPI and SPI-g-(AA-co-HPBA).
Figure 6
Figure 6
FTIR spectra of neat SPI and SPI-g-(AA-co-HPBA).
Figure 7
Figure 7
TGA/DTG of neat SPI and SPI-g-(AA-co-HPBA).
Figure 8
Figure 8
(a) SEM of neat SPI (×3.0 K) at 10 μm, (b) SPI-g-AA (×20.32 K) at 1 μm, (c) SPI-g-AA (×30.8 K) at 1 μm, (d) SPI-g-AA (×8.4 K) at 2 μm, (e) SPI-g-(AA-co-HPBA) (×2.07 K) at 2 μm, (f) SPI-g-(AA-co-HPBA) (×30.84 K) at 1 μm, (g) SPI-g-(AA-co-HPBA) (×20.0 K) at 2 μm, and (h) SPI-g-(AA-co-HPBA) (×8.15 K) at 1 μm.
Figure 9
Figure 9
TEM images: (a) neat SPI at 50 nm, (b) neat SPI at 100 nm, (c) neat SPI at 51 nm, (d) neat SPI electron image at 5 μm, (e) SPI-g-(AA-co-HPBA) at 50 nm, (f) SPI-g-(AA-co-HPBA) at 1 μm, (g) SPI-g-(AA-co-HPBA) at 51 nm, and (h) SPI-g-(AA-co-HPBA) electron image at 1 μm.
Figure 10
Figure 10
1H NMR in D2O comparison of neat SPI and SPI-g-(AA-co-HPBA).
Figure 11
Figure 11
Antibacterial activity (ZI size) of neat ciprofloxacin, SPI-g-(AA-co-HPBA) hydrogel, and ciprofloxacin-loaded SPI-g-(AA-co-HPBA) hydrogel against E. coli bacterial strain. The untreated group did not receive any treatment in the well formed on E. coli-plated agar plates.
Figure 12
Figure 12
Effect of different treatments on the viability of HepG-2 cells as evaluated by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. The control group was not subjected to any treatment and was considered to have 100% cell viability. The effect of different treatments on cell viability has been presented as per cent of control group (100%). Each value depicts an average of three sets of experiments and was expressed as mean ± SE. Significance at *P < 0.05, compared with the control (Student’s t-test).

References

    1. El-Kamel A. H.; Ashri L. Y.; Alsarra I. A. Micromatricial Metronidazole Benzoate Film as a Local Mucoadhesive Delivery System for Treatment of Periodontal Diseases. AAPS PharmSciTech 2007, 8, E184–E194. 10.1208/pt0803075. - DOI - PMC - PubMed
    1. Perioli L.; Ambrogi V.; Rubini D.; Giovagnoli S.; Ricci M.; Blasi P.; Rossi C. Novel mucoadhesive buccal formulation containing metronidazole for the treatment of periodontal disease. J. Controlled Release 2004, 95, 521–533. 10.1016/j.jconrel.2003.12.018. - DOI - PubMed
    1. Peh K. K.; Wong C. F. Polymeric Films as Vehicle for Buccal Delivery: Swelling, Mechanical, and Bioadhesive Properties. J. Pharm. Pharm. Sci. 1999, 2, 53–61. - PubMed
    1. Schwach-Abdellaoui K.; Castioni N. V.; Gurny R. Local delivery of antimicrobial agents for the treatment of periodontal diseases. Eur. J. Pharm. Biopharm. 2000, 50, 83–99. 10.1016/S0939-6411(00)00086-2. - DOI - PubMed
    1. Maheshwari M.; Miglani G.; Mali A.; Paradkar A.; Yamamura S. Development of Tetracycline-Serratiopeptidase-Containing Periodontal Gel: Formulation and Preliminary Clinical Study. AAPS PharmSciTech 2006, 7, E162–E171. 10.1208/pt070376. - DOI - PMC - PubMed